Skip to content
Medical Health Aged Care

Florey research finds association between prenatal exposure to plastics and autism in boys

Key Points 3 mins read

Common plastic associated with autism in boys 

Florey researchers have found evidence of higher levels of the plastic chemical bisphenol A (BPA) in pregnant mothers who gave birth to sons with autism.  

Research published in Nature Communications, led by Florey scientists Dr Wah Chin Boon and Professor Anne-Louise Ponsonby, supports the hypothesis of a possible link between autism and exposure to plastic chemicals in the womb. 

Professor Ponsonby said the researchers analysed two large birth cohorts – the Barwon Infant Study (BIS) in Australia and the Columbia Centre for Children’s Health and Environment in the USA.  

“Exposure to plastic chemicals during pregnancy has already been shown in some studies to be associated with subsequent autism in offspring,” Professor Ponsonby said.  

“Our work is important because it demonstrates one of the biological mechanisms potentially involved. BPA can disrupt hormone controlled male fetal brain development in several ways, including silencing a key enzyme, aromatase, that controls neurohormones and is especially important in fetal male brain development. This appears to be part of the autism puzzle.” 

The study examined children with lower levels of the enzyme aromatase, which in the brain converts testosterone to neuroestrogen, Professor Ponsonby said. 

The link between BPA presence and autism was particularly evident in the top fifth of boys with vulnerability to the endocrine-disrupting properties of this chemical. That is, those with lower levels of the enzyme aromatase. The study found boys in that group, who were born to mothers with higher urinary BPA levels in late pregnancy were: 

  • 3.5 times more likely to have autism symptoms by age 2 years.  

  • 6 times more likely to have a verified autism diagnosis by age 11 years than those whose mothers had lower levels of BPA during pregnancy. 

  • In both birth cohorts, mechanistic evidence demonstrated higher BPA levels were associated with epigenetic (gene switching) suppression of the aromatase enzyme overall. 

In laboratory work, Dr Boon studied the impact of prenatal BPA on mice. 

“We found that BPA suppresses the aromatase enzyme and is associated with anatomical, neurological and behavioural changes in the male mice that may be consistent with autism spectrum disorder,” Dr Boon said. 

“This is the first time a biological pathway has been identified that might help explain the connection between autism and BPA,” she said. 

Professor Ponsonby said BPA, similar bisphenols and other plastic chemicals with endocrine-disrupting effects are now widespread and almost impossible for individuals to avoid.  

“We all ingest plastic chemicals in many ways – through ingesting plastic food and drink packaging, inhaling home renovation fumes, and through the skin from sources such as cosmetics. There are so many ways these chemicals enter our bodies, so, it’s not surprising that BPA was present in a large proportion of the women’s urine samples we studied. It’s important for us to understand how these plastics affect our health,” Professor Ponsonby said. 

These findings are now feeding into public safety regulators which update safety recommendations on manufactured chemical exposure, including plastic chemicals, during pregnancy and early life. 

The team also looked for ways to reduce the adverse effect of BPA on the aromatase system. 

Dr Boon added that a type of fatty acid called 10-hydroxy-2-decenoic acid tested in mice could be worth further investigation.  

“10-hydroxy-2-decenoic acid shows early indications of potential in activating opposing biological pathways to improve autism-like characteristics when administered to animals that have been prenatally exposed to BPA. It warrants further studies to see whether this potential treatment could be realised in humans.”  


About us:

*Dr Boon is a co-inventor on ‘Methods of treating neurodevelopmental diseases and disorders’, USA Patent No. US9925163B2, Australian Patent No. 2015271652. This has been licensed to Meizon Innovation Holdings. Professor Ponsonby is a scientific advisor and Dr Boon is a board member of the Meizon Innovation Holdings. 

 

Contact details:
 

Kathryn Powley, Media and Communications Manager 

[email protected] | 0456 666 271 

Media

More from this category

  • General News, Medical Health Aged Care
  • 10/03/2026
  • 10:27
National Drug and Alcohol Research Centre, UNSW Sydney

Spike in deaths from novel benzos a major public health concern, NDARC study shows

Poisoning deaths from ‘novel’ benzodiazepines (NBZDs) – designed to mimic brand-name drugs like Valium and Xanax but with greater potency – have spiked in the last six years. Out of nearly 260 fatal NBZD-related toxicity cases reported since 2013, about 87% of these deaths occurred between 2020 and 2025, according to findings from the National Drug and Alcohol Research Centre, UNSW Sydney. Emeritus Professor Shane Darke, who led the study, said the rapid increase in fatal overdoses from the unregulated drugs was a major clinical and public health concern. “People who use novel benzodiazepines need to be aware that there…

  • CharitiesAidWelfare, Medical Health Aged Care
  • 10/03/2026
  • 10:00
Bowel Cancer Australia

Bowel Cancer Care with Confidence New accredited CPD Series – cpd.bowelcanceraustralia.org

163,000+ Australians are now living with or beyond bowel cancer. Access to a nurse specialist identified by more than 8 in 10 bowel cancer patients as an important resource to improve their care coordination. Tuesday, 10 March, Sydney: Committed to providing excellence in person-centred supportive care, Bowel Cancer Australia today launched its Bowel Cancer Care with Confidence CPD Series which reflects the latest evidence and optimal care for people living with bowel cancer. Co-developed with clinical experts including Specialist Bowel Care Nurses, Counsellors, Exercise Physiologists and Clinical Nutritionists and those with lived experience, the CPD Series spans the care continuum…

  • Contains:
  • General News, Medical Health Aged Care
  • 10/03/2026
  • 09:25
March 10, 2026

The sport safety warning parents can’t ignore

With collisions or falls accounting for 66 per cent of sports injury hospitalisations, dentists are urging parents and amateur athletes to get their mouthguards sorted for the 2026 season to help avoid nasty injuries. The latest government data suggests 19 per cent of participants experienced an injury while playing sport with collision-heavy codes such as AFL and Rugby having more than double the hospitalisation rate of any other recreational sport. Despite these risks, only 36 per cent of Australians wear a mouthguard when playing contact sport, and even fewer wear a mouthguard during training. Dr Mark Dohlad, Principal Dental Officer…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.